Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose simvastatin plus VAD chemotherapy in refractory or relapsed multiple myeloma
NL-OMON20029Phase 2Suspended
- Sponsor
- The study is conducted on the department of hematology in het University Medical Center Utrecht. The study is approved by the Medical Ethical Board of this same hospital.
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of simvastatin in multiple myeloma (MM), sponsored by The study is conducted on the department of hematology in het University Medical Center Utrecht. The study is approved by the Medical Ethical Board of this same hospital. Primary endpoint: Response by EBMT criteria. Started May 2005; status: suspended.
02
Drugs
simvastatin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON20029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20029.